A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

Inclusion Criteria:

• Ability and willingness to comply with all aspects of the protocol includingcompletion of the efficacy assessments (EASI and IGA), clinical outcome assessmentinstruments (DLQI, POEM), and safety and PK sample collections for the duration ofthe study

Parent Clinical Trial-Specific Criteria:

• Study CS45570 participants who continued to be evaluated at the Week 36 follow upvisit and achieved => EASI50 response from study baseline

Exclusion Criteria:

• Evidence of other skin conditions that would interfere with the assessment of AD

• Withdrawal of consent and/or premature discontinuation from parent study

• Any permanent discontinuation of study drug in parent study

• History of severe allergic reaction or anaphylactic reaction to any biologic agentor known hypersensitivity to any component of Afimkibart